Janux Therapeutics
JANX
17.92
+1.13
+6.73%
Janux Therapeutics
US · JANX
#3187 by market cap
Listed 2021
17.92
+1.13
+6.73%
Live - 5344 symbols - heartbeat 567s ago
· 2026-10-08 08:14
Pre-market
18.42
+2.79%
After-hours
18.50
+3.24%
Overnight
17.91
-0.06%
- Market cap
- 1.10B
- P/E (TTM)i
- -10.93
- P/Bi
- 1.18
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 25%
Reader sentiment
Are you bullish or bearish on JANX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 101.81% -0.10pp
- Institutions
- 253 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund44.11%
Hedge Fund27.49%
VC/PE Fund22.09%
Individual/Insider5.92%
Public Company4.49%
Private Company2.17%
Insurance Company1.16%
Government Pension Fund0.30%
Top holders as of 2026-06-30
RA Capital Management, L.P.
18.30% · 11.19M sh
BlackRock
10.03% · 6.13M sh
Prosight Management, LP
6.22% · 3.80M sh
State Street Global Advisors
4.92% · 3.00M sh
Klaus Dorner
4.91% · 3.00M sh
FMR
3.93% · 2.41M sh
Federated Hermes, Inc.
3.85% · 2.35M sh
Vanguard Capital Management, LLC
3.55% · 2.17M sh
Point72 Asset Management, L.P.
3.26% · 1.99M sh
TCG Crossover Management, LLC
2.93% · 1.79M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| RA Capital Management, L.P. | -- | 18.30% |
| Sheila Gujrathi | Director | 0.18% |
| David Campbell | Chief Executive Officer | 0.18% |
| Thomas Diraimondo | Executive Director of Research & Development | 0.17% |
| Vickie Capps | Independent Director | 0.12% |
| Andy Meyer | Chief Business Officer | 0.11% |
| Charles Winter | Chief Technology Officer | 0.10% |
| Janeen Doyle | Chief Corporate & Business Development Officer | 0.06% |
| Natasha Hernday | Director | 0.01% |
| Eric Dobmeier | Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-30 | David Campbell | Chief Executive Officer | Other Disposition | -123,840 | -- |
| 2026-07-07 | David Campbell | Chief Executive Officer | Derivative Exercise and Retained | +7,000 | $4.21 |
| 2026-06-10 | Vickie Capps | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Vickie Capps | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Ronald Barrett | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Ronald Barrett | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Eric Dobmeier | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Eric Dobmeier | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Natasha Hernday | Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Natasha Hernday | Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Winston Kung | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Winston Kung | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-10 | Jake Simson | Independent Director | Other Acquisition | +5,500 | -- |
| 2026-06-10 | Jake Simson | Independent Director | Other Derivative Acquisition | +15,500 | $13.66 |
| 2026-06-01 | Janeen Doyle | Chief Corporate & Business Development Officer | Open Market Disposition | -4,059 | $14.03 |
| 2026-05-10 | Maria Dobek | Principal Accounting Officer & VP of Accounting | Open Market Disposition | -2,038 | $14.17 |
| 2026-02-01 | William Go | Chief Medical Officer | Other Acquisition | +44,000 | -- |
| 2026-02-01 | William Go | Chief Medical Officer | Other Derivative Acquisition | +154,000 | $13.99 |
| 2026-01-01 | David Campbell | Chief Executive Officer | Other Acquisition | +96,600 | -- |
| 2026-01-01 | David Campbell | Chief Executive Officer | Open Market Disposition | -8,072 | $13.73 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:14:51 · For reference only, not investment advice and not tailored to your situation.